|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
protease inhibitor
|
|
gptkbp:administeredBy
|
gptkb:rilpivirine
gptkb:abacavir
gptkb:lamivudine
emtricitabine
tenofovir
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AX12
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:brand
|
gptkb:Dovato
gptkb:Juluca
gptkb:Triumeq
gptkb:Tivicay
|
|
gptkbp:CASNumber
|
1051375-16-6
|
|
gptkbp:chemicalClass
|
gptkb:pyrimidinone
|
|
gptkbp:contraindication
|
hypersensitivity
|
|
gptkbp:developedBy
|
gptkb:ViiV_Healthcare
|
|
gptkbp:drugInteraction
|
gptkb:metformin
gptkb:rifampin
antacids
|
|
gptkbp:eliminationHalfLife
|
14 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C20H19F2N3O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dolutegravir
|
|
gptkbp:KEGGID
|
D09964
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV integrase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2026 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:pregnancyWarning
|
possible risk of neural tube defects
|
|
gptkbp:proteinBinding
|
>98%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2176937
gptkb:DB08930
29385216
54726191
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
insomnia
|
|
gptkbp:UNII
|
GMP79G6WMR
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:INSTIs
|
|
gptkbp:bfsLayer
|
5
|